Shift in Treatment Considerations for Patients with HIV and HCV Coinfection

With direct-acting antivirals now achieving acceptable SVRs, clinicians can focus more on getting and keeping coinfected patients in treatment.

During the bygone era of interferon-based therapy, patients coinfected with HIV and hepatitis C virus (HCV) had significantly lower sustained virologic response (SVR) rates compared with HCV-monoinfected patients and were considered a difficult-to-treat population (and, per the FDA, a “special population with unmet needs”). However, with the high cure rates now afforded by direct-acting antiviral agents (DAAs), some experts are reexamining this designation.

In the current systematic review of literature published between 2004 and 2017, researchers evaluated the efficacy of various regimens used for the treatment of HIV/HCV coinfected patients. The review included studies published between 2004 and 2017.

In nearly every study reviewed, interfe…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Shift in Treatment Considerations for Patients with HIV and HCV Coinfection

Topics

Reviewing Author